The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.b

Opportunistic pulmonary/systemic infections

See PMID 27836224

Publications

Do H, Pyo JY, Sup, Sup, Song JJ, Sup, Sup, Park YB, Sup, Sup, Lee SW, Sup, Sup

Implication of Serious Infections in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the First Cycle of Rituximab: A Pilot Study in a Single Korean Center.

Journal of rheumatic diseases. 2023;30(1):45-52

Gulleroglu K, Baskin E, Moray G, Ozdemir H, Arslan H, Haberal M

Rituximab Therapy and Infection Risk in Pediatric Renal Transplant Patients.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. 2016;14(2):172-5

Heusele M, Clerson P, Guery B, Lambert M, Launay D, Lefevre G, Morell-Dubois S, Maillard H, Le Gouellec N, Hatron PY, Hachulla E

Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab.

Clinical rheumatology. 2014;33(6):799-805

Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, Nicholson AG, Hansell DM, Wells AU, Renzoni EA

Rituximab in severe, treatment-refractory interstitial lung disease.

Respirology (Carlton, Vic.). 2014;19(3):353-9